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Arginine-rich cell-penetrating peptides are short cationic peptides capable of traversing the plasma
membranes of eukaryotic cells. While successful intracellular delivery of many biologically active
macromolecules has been accomplished using these peptides, their mechanisms of cell entry are
still under investigation. Recent dialogue has centered on a debate over the roles that direct trans-
location and endocytotic pathways play in internalization of cell-penetrating peptides. In this paper,
we review the evidence for the broad range of proposed mechanisms, and show that each distinct
process requires negative Gaussian membrane curvature as a necessary condition. Generation of
negative Gaussian curvature by cell-penetrating peptides is directly related to their arginine con-
tent. We illustrate these concepts using HIV TAT as an example.
 2009 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Cellular uptake of biologically active molecules is a major obsta-
cle in pharmaceutical drug design and controlled drug delivery.
While a broad range of therapeutic agents, including proteins, pep-
tides and oligonucleotides, have been successfully introduced to
target cells using viral vectors [1], and methods such as electropor-
ation, microinjection, and liposome encapsulation [2], these inter-
nalization strategies have a number of drawbacks. Problems
include inefﬁcient drug delivery, high variability of drug expres-
sion among target cells, cellular damage and toxicity, and restric-
tions based upon drug and cell type. The ﬁrst barrier to efﬁcient
and controlled intracellular delivery is the plasma membrane
which prevents direct translocation of hydrophilic macromole-
cules. In vivo, the most common pathway for bringing a macromol-
ecule into a cell is through endocytosis. However, the fate of an
endocytosed macromolecule is unpredictable; it may remain
trapped in endosomes and suffer degradation by the acidic pH
and digestive enzymes.on behalf of the Federation of Euro
nt of Bioengineering, Univer-
s Angeles, CA 90095, United
).
CLA, Los Angeles, CA 90095,Biology has evolved ways to circumvent these problems as a
number of proteins are permeable to mammalian cell membranes.
This ability is conferred by a localized region in the protein known
as the protein transduction domain. Furthermore, the isolated
peptide sequence, sometimes referred to as a cell-penetrating
peptide, retains the transduction properties of the native protein.
These cell-penetrating peptides comprise a class of short (<20
amino acid) cationic peptides that have the ability to traverse
the cell membranes of many different types of mammalian cells.
A wide variety of macromolecules have been attached to these
peptides and subsequently internalized. Moreover, after uptake
the cargo maintains its activity. The ability of cell-penetrating
peptides to translocate biologically active molecules into cells
makes these peptides promising candidates for drug delivery
applications.
Among the cell-penetrating peptides, the arginine-rich cell-pe-
netrating peptides have been the most widely studied [3,4]. Exam-
ples include the TAT peptide from the HIV transactivator protein
TAT, Penetratin, a 16 amino acid domain from the Antennapedia
protein of Drosophila, a ﬂock house virus (FHV) coat peptide (se-
quence 35–49), and oligoarginines [3,5]. In this review, we focus
on TAT peptide, partly because it has attracted the most attention,
but also because it is a prototypical example that has many of the
essential characteristics of the arginine-rich cell-penetrating pep-
tides. This is not to say all cell-penetrating peptides behave in
the exact same manner, nor do they exhibit identical activity pro-
ﬁles. Rather we propose that the structure function relationshipspean Biochemical Societies.
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nine-rich peptides.2. TAT as a prototypical example of a cell-penetrating peptide
In 1988, Green and Lowenstein [6], and Frankel and Pabo [7],
independently discovered that the transactivator of transcription
(TAT) protein of the Human Immunodeﬁciency Virus can penetrate
cells and activate the viral genome replication. The TAT protein is
an 86 amino acid long protein that is released by infected cells
and is an essential regulatory gene for HIV replication [8]. In
1997, Vives et al. [9] found that a 11-amino acid sequence, TAT
(47–57), now known as the TAT peptide or TAT PTD, can not only
enter cells but is more efﬁcient than the full length protein. It
was observed that the chirality of the peptide backbone has no ef-
fect on cellular uptake of TAT peptide; inverse and retro forms
were able to enter cells as efﬁciently as the native peptide, suggest-
ing uptake does not require a speciﬁc binding site. The TAT peptide
can enter cells efﬁciently, either alone or linked to macromolecules
like proteins, oligonucleotides or liposomes. TAT-mediated deliv-
ery appears to be independent of cargo size. Proteins in excess of
100 000 Da, 40 nm nanoparticles and even 200 nm liposomes have
been delivered inside cells using TAT peptide. The liposomes were
intact inside the cells and remained so even 1 h after transduction.
Conversely, non-conjugated proteins in the incubation media were
not able to enter cells [10].
TAT peptide is highly cationic with 6 arginine and 2 lysine res-
idues. Substitution of any basic residue with neutral alanine re-
duces activity, while substitution of neutral residues has no
effect, implying the net positive charge of TAT is necessary for cel-
lular uptake. It has been hypothesized that the utility of being pos-
itively charged likely comes from the resulting strong electrostatic
interactions with the plasma membranes of eukaryotic cells. Stud-
ies on the binding afﬁnities of cationic cell-penetrating peptides
indicate these peptides strongly bind electrostatically to the vari-
ous anionic species present at the extracellular surface of cell
membranes, including lipid head groups, proteins like nucleolin,
and proteoglycans such as heparin sulfate [11,12].
Although electrostatic interactions are known to be important
for arginine-rich cell-penetrating peptides, non-electrostatic ef-
fects such as hydrophobicity and peptide structural transitions
can also contribute to the binding afﬁnity of amphipathic cell-pe-
netrating peptides to cell membranes [13]. For example, Penetratin
adopts a random coil structure in solution, and transforms to an a-
helical conformation at high lipid to peptide molar ratios [14,15].
Moreover, decreasing the lipid to peptide ratio promotes a higher
degree of b-sheet conformation [15]. Both of these secondary
structural transitions increase the amphipathicity of Penetratin,
allowing its hydrophobic moieties to directly interact with the
non-polar interior of the lipid membrane, and several studies have
implicated insertion of the hydrophobic portions of Penetratin into
the membrane as being important for uptake [16–18]. In contrast,
the non-amphipathic TAT peptide is unstructured both in solution
and when associated with lipid membranes [19], and TAT associ-
ates with the membrane surface since hydrophobic interaction is
negligible [11].
It is empirically known that the cationic nature of the peptide is
a necessary condition but not a sufﬁcient condition for transloca-
tion activity. Although, arginine-rich oligomers can enter cells,
similar length polymers of other basic amino acids, lysine, orni-
thine or histidine, cannot [20]. Branched chain arginine polymer
is as efﬁcient as the corresponding linear polymer. However, pep-
tide length is an important factor [21]. The efﬁciency of cellular up-
take depends on the number of arginine residues. Arginine
polymers with less than ﬁve amino acids are not as effective aspolymers with six or more amino acids. Uptake efﬁciency increases
as the peptide length increases up to 15 amino acids. Peptides with
more than 15 arginine residues can still enter cells but with signif-
icantly less efﬁciency [20,22]. The guanidinium head group of argi-
nine is the central structural feature required for peptide uptake.
Heptamers of citrulline, an isotere of arginine with a nitrogen of
guanidine replaced by oxygen, are unable to enter cells [20].
The discovery that the guanidinium residues of arginine are the
essential ingredients of a peptide’s ability to enter cells has allowed
for the design of a range of guanidinium-rich synthetic analogs.
Oligoarginine peptoids that have the side chain attached to nitro-
gen instead of carbon have proved to be more efﬁcient than oli-
goarginines [21]. Guanidinium-rich oligocarbamates were taken
up into cells about three times faster than TAT peptide [23]. Poly-
guanidino dendrimers, based on diamino acid monomeric units,
have also proven to be effective at entering cells [24]. Carbohy-
drate-based polymers like the guanidinylated neomycin can not
only enter cells but can carry large (>300 kDa) bioactive macromol-
ecules along [25]. Recently, Deming and co-workers [26] combined
liposome drug delivery system with cell-penetrating peptides by
preparing polyarginine–polyleucine block copolymers that self-
assemble into vesicles. The vesicles remained intact inside the cells
showing their potential to carry large cargoes. Although long pol-
yarginine chains (>20) are thought to be less efﬁcient for intracel-
lular delivery, they facilitated cellular uptake of the vesicles.3. Direct translocation, endocytosis: an either/or discourse?
The exact molecular mechanism of cellular entry of arginine-
rich cell-penetrating peptides is currently not fully understood. Ini-
tial studies indicated a direct translocation mechanism across the
cell membrane that bypassed endocytosis. Fluorescence micros-
copy and ﬂuorescence activated cell sorting (FACS) studies on cells
incubated with ﬂuorescently-labeled peptides showed rapid trans-
location that was not inhibited when cells were incubated at 4 C.
Addition of metabolic or endocytosis inhibitors also seemed to
have no effect on cellular internalization. These experiments, along
with the ﬁnding that inverse and retro forms of the peptide are as
effective, led to the belief that cellular uptake involved an energy-
independent, non-endocytotic process that was receptor indepen-
dent [4,9,10,20].
Most of these early experiments were conducted using micros-
copy or ﬂow cytometry on ﬁxed cells. In 2003, Richard et al. [27]
showed that a mild ﬁxation of cells with formaldehyde drastically
changed the intracellular distribution of TAT peptide. Fixed cells
showed nuclear localization of TAT peptide while unﬁxed cells
had the peptide located in cytoplasmic vesicles. Additionally, it
was shown that ﬂow cytometry was unable to distinguish between
membrane-bound and internalized ﬂuorochrome. In living, non-
ﬁxed cells analyzed with FACS, a large fraction of the ﬂuorescent
peptide was associated with the outer leaﬂet of the cell membrane
instead of being present within the cytoplasm. They demonstrated
that trypsin treatment of cells removed surface-bound peptide by
digesting the peptide. FACS analysis following trypsin treatment
indicated a relatively slow rate of uptake, comparable to that of
classical markers of endocytosis. Since then, many other studies
have also observed inhibition of cellular uptake at 4 C and with
chemical means that induce energy depletion, indicating an en-
ergy-dependent process as the major route for the internalization
of cell-penetrating peptides [27–33].
Many groups have proposed that cell membrane heparan sul-
fate proteoglycans (HSPGs) act as receptors for extracellular TAT
uptake. Proteoglycans are negatively charged, and are present on
the surface of many cell types. Thermodynamic studies have
shown that TAT binds with signiﬁcantly greater afﬁnity to heparin
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with different components of the membrane suggests that multi-
ple mechanisms are possible. Moreover, it has been observed that
interaction with the cell-penetrating peptides results in aggrega-
tion of both anionic lipids and proteoglycans, which may provide
further clues for the nature of the alternate mechanisms [34,35].
Ligands that bind to proteoglycans can be internalized through
an endocytotic pathway. Both TAT protein and TAT peptide were
shown to bind strongly to heparin, a sulfated glycosaminoglycan
that mimics the heparan sulfate proteoglycans [36,37]. It was also
demonstrated that addition of heparin and dextran, another sul-
fated glycosaminoglycan, inhibits the cellular uptake of TAT pep-
tide [31,38,39]. Treatment of cells with chemicals that eliminate
or cleave the HS proteoglycans resulted in a signiﬁcant decrease
in TAT peptide internalization [40]. Studies with mutant cells that
are unable to synthesize glycosaminoglycans showed reduced TAT-
mediated transport [39,41,42]. These studies suggest that heparan
sulfate can act as a receptor for TAT peptide, and constitutes an
important pathway for internalization; however, none of the stud-
ies have demonstrated complete inhibition of cellular uptake [41].
In addition, polyarginine was able to enter mutant cells that have
less than 2% of the wild-type level of heparin sulfate [25]. This sug-
gests the presence of a heparan sulfate-independent pathway in
addition to a heparan sulfate-dependent one.
Analysis of peptide uptake by live-cell microscopy has demon-
strated the involvement of endocytosis in the cellular internaliza-
tion of the TAT peptide. Within the broad classiﬁcation of
endocytosis, there are several possible mechanisms of uptake.
Studies on TAT peptide uptake in cells with speciﬁc endocytotic
pathways chemically inhibited have yielded mixed results. Clath-
rin-mediated endocytosis has been proposed as the primary mech-
anism of uptake of arginine-rich transporters. Clathrin-mediated
endocytosis is the major and best-characterized endocytotic path-
way. It involves strong binding of a ligand to a speciﬁc cell surface
receptor resulting in the clustering of the ligand–receptor com-
plexes in coated pits on the plasma membrane, formed by the
assembly of clathrin. The coated pits then invaginate and pinch
off from the plasma membrane to form intracellular clathrin-
coated vesicles [43]. It has been reported that in HeLa cells, labeled
cell-penetrating peptides colocalize with transferrin, a glycopro-
tein marker for endocytosis [27,44]. Another study demonstrated
that TAT uptake in HeLa cells in the presence of chlorpromazine,
a known inhibitor of clathrin-mediated endocytotic pathway, re-
sulted in a 50% inhibition of peptide uptake, while incubation in
a potassium-free buffer resulted in a 40% decrease, indicating the
involvement of clathrin-dependent pathway [33]. However, other
studies with ﬂuorescently labeled polyarginine conjugates
[30,45] and fusion proteins [41,46] showed that it does not colocal-
ize with transferrin. Another study with a TAT-avidin conjugate
showed only a modest decrease in uptake upon treatment with
hyperosmolar medium, a condition shown to decrease clathrin-
dependent endocytosis [47].
Caveolin-dependent endocytosis, a lipid raft-mediated form of
endocytosis has likewise been implicated. Caveolae are small,
hydrophobic membrane microdomains that are rich in cholesterol
and glycosphingolipids. Ligands associate with the cell membrane
and then become trapped in relatively stationary caveolae, which
then bud off the membrane and form caveosomes. Cholesterol is
required for caveolar uptake and drugs that speciﬁcally bind to
cholesterol perturb internalization through the caveolae [43].
TAT-GFP in HeLa cells [46] and in CHO-K1 and HL3T1 cells [41]
has been shown to colocalize with caveolin-1. Both TAT-rhodamine
[45] and TAT-GFP [41] complexes have also been shown to colocal-
ize with cholera toxin, which is known to proceed through a cave-
olin-dependent pathway. However, nystatin, a compound known
to inhibit caveolae formation, and ﬁlipin III had little effect onthe uptake of ﬂuorescently labeled TAT into HeLa cells or CHO cells
[33].
A number of research groups have proposed macropinocytosis
as the mechanism of uptake for cell-penetrating peptides. Macr-
opinocytosis involves the formation of large endocytotic vesicles
of irregular size and shape, generated by actin-driven envagination
of the plasma membrane. Macropinosomes have no coat and do
not concentrate receptors. They vary in size, sometimes being as
large as 5 lm in diameter [43]. Studies have shown dose-depen-
dent inhibition of TAT peptide uptake when cells are pretreated
with amiloride, an inhibitor of the Na+/H+ exchange required in
macropinocytosis, or cholesterol is removed with b-cyclodextrin
[32,48]. Additionally, cytochalasin D, an inhibitor of actin polymer-
ization, and the macropinocytosis inhibitor ethylisopropylamilo-
ride have been shown to signiﬁcantly suppress uptake of the
arginine-rich peptides into HeLa cells [30]. However, Zaro et al.
[49] reported that delivery of oligoarginine in HeLa cells was not
inhibited by incubation at 16 C, or by treatment with amiloride
indicating a mechanism different from macropinocytosis.
Although the direct translocation mechanism from earlier stud-
ies has been shown to be an artifact of cell ﬁxation and membrane-
associated peptide, studies on live, non-ﬁxed cells have indicated
the presence of a non-endocytotic mechanism of cellular uptake
of cell-penetrating peptides. Maiolo et al. [50] used confocal
microscopy to study the cellular distribution of arginine-rich cell-
penetrating peptides in live cells. They found that the uptake
characteristics were a mixture of punctate and diffuse staining.
Incubating the cells at 4 C eliminated most of the punctate stain-
ing, indicating that it is due to endocytotic uptake. The diffuse
staining appeared to be fast and occurred at both 37 and 4 C, indi-
cating a second, non-endocytotic mechanism. The diffuse staining
was not due to the release of peptide from endosomes as it
appeared ﬁrst and the punctate staining later, and it continued to
occur at 4 C when endocytosis is inhibited. Several other studies
have also reported cellular uptake when the cells have been incu-
bated at 4 C [26,51–53]. It has also been observed that blocking
speciﬁc endocytotic pathways does not affect the ability of TAT
peptide to enter cells.
Examination of translocation of arginine-rich cell-penetrating
peptides across unilamellar vesicles as a model system has re-
vealed a range of behavior. Several early studies have indicated
that the addition of both TAT peptide [11,54] and Penetratin
[55,56] do not induce dye leakage and are not directly translocated
in lipid vesicles composed mainly of zwitterionic PC and anionic
PG and PS lipids. Membrane potential measurements also indicate
that lipid bilayers with similar compositions remain intact [34].
Recent results suggest that the lipid composition of the target
membrane is important for transduction activity. We have directly
observed TAT peptide entry into giant unilamellar vesicles without
any endocytotic machinery, provided that the target membranes
have negative intrinsic curvature lipids (such as those with PE head
groups) at concentrations above a minimum ‘threshold’ concentra-
tion [57]. This has also been observed with Penetratin, which tra-
verses lipid bilayers containing PE lipids [58].
A number of studies have investigated the question of how cell-
penetrating peptides dissociate from the plasma membrane once
they are internalized. For example, it has been shown that the argi-
nine-rich peptide, R8W, can strongly interact with the anionic cel-
lular cytoskeleton components actin and tubulin, leading to
aggregation [59]. The TAT peptide also binds to and condenses
DNA. Moreover, the binding constant for the TAT peptide with
DNA is 1–2 orders of magnitude higher than for heparin sulfate,
leading to the hypothesis that high DNA-binding afﬁnity could
facilitate the release of cargo after cellular uptake [60], by promot-
ing competition for the membrane association of polycationic
peptides.
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mostly notably TAT, has often been characterized by a type of
‘either/or’ discourse, such as the whether direct translocation or
some speciﬁc form of endocytosis is most relevant. Since the cellu-
lar uptake of arginine-rich peptides is dependent on a variety of
factors, including temperature, incubation time, cell type, cargo
type and size, linkage type and size [4,61], comparison between
different experiments have been difﬁcult, and has compounded
the controversy surrounding the uptake mechanism. It has no
doubt been recognized that more than one mechanism may be in-
volved in TAT translocation activity. This recognition accommo-
dates the broad range of proposed hypotheses, and can
potentially conclude the discourse with an artiﬁcial consensus.
However, an acknowledgement of multiple mechanisms of entry
does not explain the central phenomenon: How does a relatively
simple molecule like TAT facilitate mechanisms as different as di-
rect entry and the multiple endocytotic mechanisms? Rather than
debate the differences between the distinct observed mechanisms,
we focus on what these different mechanisms have in common,
and relate these common features to what the physical chemistry
of cell-penetrating peptides allows them to do.4. Peptide–membrane interactions
4.1. Electrostatics
Electrostatics in aqueous environments is counterintuitive. At
physiological conditions, electric ﬁelds from cell-penetrating pep-
tides are strongly reduced by the large dielectric constant of
water, and by screening from ions from dissociated salts. That is
not to say that electrostatic interactions are weak. The entropy
of ions can result in strong interactions between charged objects
in water despite short screening lengths, via coupling between os-
motic and electrostatic interactions. For example, the attraction
between a cationic cell-penetrating peptide and an anionic mem-
brane is driven by the entropy gain from release of condensed
counterions. A ﬂat, charged membrane is covered on both sides
by a layer of condensed counterions (the ‘Gouy–Chapman’ layer),
consistent with the non-linear Poisson–Boltzmann equation [62].
A similar analysis reveals that charged polymers are also coated
by a layer of condensed counterions (the ‘Manning layer’) [63].
In the present case of cell-penetrating peptide adsorption onto
an oppositely charged membrane, the complementary charge dis-
tributions can electrostatically compensate one another. This
means that condensed counterions are no longer needed by the
membrane and the polymer at the regions of contact, and thus
can be released for a large entropic gain. The sequence of events
outlined above leads to a strong electrostatic attraction. This type
of electrostatic interaction has been observed for self-assembled
complexes between membranes and a variety of anionic poly-
mers, including DNA [64–66], F-actin [67], microtubules [68],
and ﬁlamentous phages [69].4.2. Induced membrane deformation
In general, the trade-off between electrostatic interactions and
membrane deformations control the interactions between charged
polymers and membrane systems [64,65,67,68]. Since counterion
release is maximized when the cationic lipids are closely associ-
ated with the anionic charges on a polymer or an oligomer, electro-
static binding favors a state where the membrane wraps around a
charged oligomer, which leads to maximal contact and maximal
entropy gain from counterion release. However, the wrapped
conﬁguration is resisted by the elastic cost of deforming the
membrane. The energetic penalty from membrane curvaturedistortions is usually described using the treatment introduced
by Helfrich [70].
The curvature elastic energy per unit area of bending a mem-
brane is given by:
f ¼ 2jðH  c0Þ2 þ jGK
where H ¼ 1
2
c1 þ c2; K ¼ c1c2
Here c1 and c2 are the principal curvatures at a point on the sur-
face. Geometrically, at any point on the surface, we can deﬁne
c1 = 1/R1, and c2 = 1/R2 where R1 and R2 are the principle radii of
curvature; the radii of circles constructed which best ﬁt the mini-
mum and maximum curvatures at the point on the surface. For
smooth surfaces c1, and c2 are in perpendicular directions. The
mean curvature is deﬁned by H, and is a measure of the degree
of membrane bending. (For example, since c1 = 1/R1: when the cur-
vature c1 is large, R1 is small, and implies a tight bend.) The Gauss-
ian curvature, K, is deﬁned by the product of c1 and c2. This type of
curvature is related to the topological changes of the membrane,
such as pore formation. (More on this later.) The mean curvature
that minimizes the free energy, c0, is called the ‘intrinsic curvature’
of the membrane. The bending modulus, j, is the energy cost of
deviating from the spontaneous curvature and the Gaussian curva-
ture modulus, jG, measures the energy cost of topological changes
[71,72]. This last quantity is an important parameter that governs a
membrane’s tendency for pore formation, for example.
In accord with intuition, the intrinsic curvature c0 of a mem-
brane depends on the shape of the lipid molecule. For c0 < 0, the
lipids are shaped like trafﬁc cones, with small head groups and
bulky tails, and tend to bend toward the hydrophilic side. For
c0 > 0, the lipids are shaped like ice-cream cones, with bulky head
groups and small tails, and tend to bend toward the hydrophobic
side. Lipids such as zwitterionic dioleoylphosphatidylcholine
(DOPC), cationic dioleoyltrimethylammonium-propane (DOTAP),
and anionic dioleoylphosphatidylglycerol (DOPG) and dioleoyl-
phosphatidylserine (DOPS), have head group areas approximately
the same as their tails and therefore have zero intrinsic curvature.
They assemble to form ﬂat membranes. Conversely, dioleoylphos-
phatidylethanolamine (DOPE) lipids have a head group smaller
than their tail region, giving them negative intrinsic curvature [73].5. Signiﬁcance of Gaussian membrane curvature for pore
formation and other cellular processes
It can be seen that formation of a pore in a membrane requires
the generation of negative Gaussian curvature (K < 0). Illustration
of this point can be seen by recalling that K at a point on the mem-
brane is the product of the two principle axes of curvature at that
point. Therefore, K < 0 implies the principle axes of curvature at a
given point must curve in opposite directions, so that the mem-
brane is locally shaped like a saddle (Fig. 1a). This is the type of cur-
vature seen objects with holes, for example a torus: the ‘hole’ of the
torus is composed of regions with saddle-shaped curvature. In con-
trast, objects such as spheres have no holes, and have K > 0 every-
where on their surface (Fig. 1b).
In a more general compass, it can be seen that negative Gauss-
ian curvature is broadly enabling. While negative Gaussian curva-
ture is topologically necessary for pore formation (Fig. 1c) it can be
seen in other processes. From Fig. 1, it can be seen that generation
of negative Gaussian membrane curvature is a necessary condition
for the dimples for caveoli-based endocytosis, for the cytoskeleton-
driven protrusions in macropinocytosis, as well as for pore forma-
tion. The Gauss–Bonnet theorem shows that if pores do not form,
the net change in the global Gaussian curvature of the membrane
is zero, i.e. D
R
K  dA = 0: if one region of the membrane develops
Fig. 1. Examples of (a) negative Gaussian curvature and (b) positive Gaussian curvature. The former is saddle shaped and found in objects with holes such as a donut. The
latter is found on objects like spheres or ellipsoids, and do not have holes. Negative Gaussian curvature is topologically necessary for the formation of (c) membrane pores, (d)
membrane dimples or invaginations (such as those in endocytosis), and (e) membrane protrusions (such as those in macropinocytosis).
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negative Gaussian curvature to exactly compensate for the distor-
tion. Examples of this balance of curvatures constrained by topol-
ogy can be seen in proposed types of TAT entry mechanisms. The
invaginations in a cell’s plasma membrane surface during endocy-
tosis display negative Gaussian curvature along the rim of the
enclosure (Fig. 1d) while the ‘pocket’ is sphere-shaped with posi-
tive Gaussian curvature. For cellular uptake processes such as
macropinocytosis, the positive Gaussian curvature at the tip of pro-
trusions is countered by the negative Gaussian curvature found at
the base of the extension (Fig. 1e). Now that we see how these neg-
ative Gaussian membrane distortions are implicated in direct pore
formation, invaginations from endocytosis, protrusions from macr-opinocytosis, the next question is, what is the relation between this
type of curvature and cell-penetrating peptides.6. The arginines in the TAT peptide generate negative Gaussian
curvature
In our recent work, we have shown that the HIV TAT cell-pene-
trating peptide generates negative Gaussian membrane curvature,
the type of membrane curvature found in pores, protrusions from
macropinocytosis, invaginations from endocytosis [57]. Using
synchrotron small angle X-ray scattering (SAXS), we demonstrated
that the TAT peptide (amino acid sequence: YGRKKRRQRRR)
Fig. 2. Synchrotron X-ray diffraction studies show that the HIV TAT cell-
penetrating peptide induces negative Gaussian curvature on membranes. This
structural tendency can lower the free energy barrier for a broad range of different
entry mechanisms.
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tive intrinsic curvature lipids. This structural tendency to form a
cubic phase can in fact be observed in other agents in different bio-
logical contexts. For example, under speciﬁc lipid compositions
and solution conditions, pore forming antimicrobial peptides ala-
methicin [74], gramicidin S [75,76], lactoferricin (LF11) derived
peptides, VS1–13 and VS1–24 [77], as well as protegrin-1 and pep-
tidyl-glycylleucine-carboxyamide [78] will also induce cubic
phases. It is interesting to note that the negative Gaussian curva-ture necessary to form these observed cubic phases is also the
structural ingredient topologically required for pore formation.
Before addition of TAT peptide a broad diffraction feature is
seen (Fig. 2a, bottom). This is consistent with the form factor of a
lipid bilayer indicating the presence small unilamellar vesicles.
After addition of TAT peptide, the spectra display correlation peaks
(Fig. 2a, middle) which show good agreement with those expected
for a cubic Pn3m ‘double-diamond’ lattice (Fig. 2b), which is rich in
negative Gaussian curvature. The cubic Pn3m is a bicontinuous
phase characterized by two non-intersecting tetrahedral networks
of water channels separated by a lipid bilayer [79]. The bilayer sur-
face between membrane leaﬂets has zero mean curvature but neg-
ative Gaussian curvature (Fig. 2c). By ﬁtting the slope of the
measured peak positions we calculate a lattice spacing of
a = 10.97 nm, for TAT peptide. Similar features are seen in the pres-
ence of 100 mM NaCl indicating that TAT peptide can generate
these dramatic changes in membrane topology at physiological salt
conditions (Fig. 2a, top).
If the generation of negative Gaussian curvature is correlated
with cell-penetrating peptide permeation ability, then peptides
that are unable to penetrate cells should not induce phases with
negative Gaussian curvature in membranes. Experiments with pol-
ylysine, K8, on membranes of identical composition to those used
for TAT peptide, show interactions between the lipid head groups
and polylysine induce wrapping of the membrane monolayers
[57]. The result is an inverted hexagonal phase where the much
smaller columnar channels are ﬁlled with peptide and solution.
This phase has negative mean curvature but zero Gaussian curva-
ture. The absence of negative Gaussian curvature may explain
the poor transduction ability of polylysine.
Comparison of arginine and lysine side chains reveals the
molecular origins responsible for differences in peptide interaction
with lipid membranes. Arginine is the most basic of all amino
acids, because its side chain ends with a guanidinium group. Struc-
turally guanidinium is characterized by a planar Y-shape which
acts to delocalize its cationic charge. The result is a moiety with
six potential hydrogen bonding sites. The multiple hydrogen bond-
ing abilities as well as its unique shape allow a guanidinium group
to direct both electrostatic and hydrogen bonding with anionic and
polar molecules [80]. When arginine interacts with phospholipids
this takes the form of bi- or multi-dentate hydrogen bonding from
simultaneous association with the phosphates of more than one li-
pid head group. However, lysine has an amino group which only
forms monodentate hydrogen bonds and therefore interacts with
the phosphate on a single lipid head group. In other words, guan-
idinium is more efﬁcient at interacting with bulky lipid head
groups. It is well known that this can lead to buckling of the pep-
tide and generate positive curvature along its length. Since the ef-
fect of a cationic peptide on an anionic membrane is create a
tendency for the membrane to wrap around the peptide, both pol-
yarginine and polylysine can generate negative mean curvature
perpendicular to their length. However, since only arginine can
form bi-dentate hydrogen bonds, an arginine-rich cell-penetrating
peptide can bond with more zwitterionic and anionic lipids and
therefore generate positive curvature along its contour length, thus
resulting in negative Gaussian curvature [81], which is manifested
in cell-penetrating peptide generation of the Pn3m cubic phase. In
addition to HIV TAT peptide, experiments with other arginine-rich
cell-penetrating peptides ANTP Penetratin and polyarginine also
show similar behavior [82].
The structural tendency of a membrane to form negative Gauss-
ian curvature under the inﬂuence of TAT cell-penetrating peptide
has a signiﬁcant dependence on membrane curvature. This may
explain the range of observed results ranging from strong translo-
cation activity to no translocation activity in biophysical experi-
ments. For example, X-ray diffraction data show a strong
1812 N. Schmidt et al. / FEBS Letters 584 (2010) 1806–1813dependence on membrane lipid composition and phase behavior.
The Pn3m cubic phase is generated by TAT peptide in membranes
enriched with negative intrinsic curvature lipids. Substitution of
DOPE (c0 < 0) with DOPC (c0 = 0) makes the intrinsic curvature of
the membrane monolayers less negative which results in the loss
of the negative Gaussian curvature-rich Pn3m phase. Moreover, di-
rect translocation of TAT peptide into the interior of giant unila-
mellar vesicles (GUVs) was likewise shown to depend on a
minimum threshold amount of membrane PE content [57]. As an-
other example, high cholesterol membrane content has been
shown to accompany each type of receptor-independent endocy-
totic pathway implicated in cell-penetrating peptide uptake,
including lipid raft-mediated caveolae and macropinocytosis
[32,83] as well as clathrin coated pit endocytosis [84]. We ﬁnd that
the presence of cholesterol at typical eukaryotic values will drasti-
cally enhance the ability of a membrane to form negative Gaussian
curvature necessary for these mechanisms [82].
7. Outlook
In this brief synopsis, we have reviewed some of the represen-
tative work on the mechanism of cell-penetrating peptides. Rather
than focusing on differences between the distinct observed mech-
anisms of entry (such as direct translocation, and various endocy-
totic mechanisms) we have instead concentrated on what these
different mechanisms have in common in terms of membrane
topology, and related these common features to what the physical
chemistry of cell-penetrating peptides allows them to do. We ﬁnd
that negative Gaussian membrane curvature is broadly enabling.
The induction of such curvature can lower the free energy barriers
for a range of different entry mechanisms, such as direct transloca-
tion as well as endocytotic pathways. Indeed, it is possible that
cell-penetrating peptides interact with cells in other important
ways besides induction of membrane curvature. For example,
one of the neglected biophysical aspects of TAT is its high positive
charge density. TAT can have strong electrostatic interactions with
different components of the cell besides the cell membrane, in
ways that contributes to its activity. Useful reviews of electrostatic
interactions in biological physics include [85–90].
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